Traditional approaches to target-driven drug discovery assume that a ‘druggable’ protein is one that possesses a deep binding pocket to accommodate a high-affinity small molecule ligand. Unfortunately, only ~20% of all proteins are druggable by these standards and less than 5% of proteins currently have a ligand that meets minimum potency and selectivity requirements. As genome-wide association studies continue to reveal potential drug targets—many of which engage in protein-protein interactions—demand has increased for the development of high-quality chemical probes to study and validate these targets. Our group aims to meet this challenge by using concave synthetic structures to target protein surfaces. By creating molecules with built-in pockets, we can target pocketless proteins of high biomedical priority that have proven refractory to traditional medicinal chemistry approaches. Our approach combines creative molecular design with robust organic synthesis methodology to generate libraries of highly functionalized and topologically unique structures. High-throughput screening methods are then employed to rapidly identify structure-function relationships and reveal fundamental principles of protein surface recognition.
Ph.D., University of Missouri-St. Louis, 2016
B.S., Indiana University, 2009
NIH Postdoctoral Fellow, New York University, 2020